Mycobacterium Tuberculosis Rifampicin Resistance Detection Kit (PCR-Melting Curve Method) CapitalBio

Features

• Rapid: The whole workflow takes only 2.5 h;

• Sensitive: The LOD is as low as 200 CFU/ml with the content of rifampicin-resistance strain≥25%;

• Simple: Compatible with DxLab-32A Automated Nucleic Acid Purification and Real Time PCR System, enabling a sample in-report out workflow

Test Method

This kit is based on PCR-melting curve Technology

Sample Types

Sputum

Clinical Significance

• Early detection of RIF resistance tuberculosis (TB) to reduce the spread of drug-resistant tuberculosis.

• Administer precise medications to RIF resistance TB patients to effectively avoid the abuse of anti-tuberculosis drugs.

• Shorten tuberculosis treatment duration, and reduce mortality rate and medical cost.

Order Information

Background Information

Antimicrobial resistance is an emerging global threat that affects infection treatments. According to the estimation of World Health Organization (WHO), in 2021 alone, there were 450,000 new tuberculosis cases (TB) resistant to rifampicin globally. The majority of the rifampicin drug resistance associated mutations occur in the RNA polymerase B subunit (rpoB) of Mycobacterium tuberculosis (MTB), which changes the core transcription machinery of the bacterium has profound effects on bacterial physiology and metabolism. Additionally, clinical reports note differences in the immune responses of patients infected with drug-sensitive or drug-resistant MTB. Emerging evidence from animal models suggest that downstream effects of rpoB mutations change host-pathogen interactions, immune responses, pathology, and outcomes.